Skip to main content

Advertisement

Table 2 Cell cycle progression of NCI-H28 cells treated with ZOL and/or Ad-delE1B55

From: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

Time (hrs) Treatment Cell cycle distribution (% ± SE)
Sub-G1 G1 S G2/M >4 N
24 (−) 8.57 ± 0.34 57.61 ± 1.07 15.48 ± 0.53 16.96 ± 0.89 0.92 ± 0.21
  Ad-LacZ 0.17 ± 0.02 58.59 ± 0.71 18.33 ± 0.19 22.24 ± 0.39 1.18 ± 0.17
  Ad-delE1B55 0.25 ± 0.10 59.35 ± 0.68 20.28 ± 0.08 15.33 ± 0.38 5.45 ± 0.19
  ZOL 0.16 ± 0.03 61.76 ± 0.64 25.71 ± 0.31 212.15 ± 0.48 0.89 ± 0.05
  ZOL + Ad-LacZ 0.15 ± 0.03 67.62 ± 0.48 21.85 ± 0.35 9.87 ± 0.20 0.96 ± 0.07
  ZOL + Ad-delE1B55 0.23 ± 0.03 65.45 ± 0.73 17.33 ± 0.21 14.21 ± 0.38 3.24 ± 0.24
48 (−) 2.79 ± 0.15 75.8 ± 0.13 9.30 ± 0.05 13.66 ± 0.20 0.93 ± 0.06
  Ad-LacZ 0.24 ± 0.01 73.42 ± 0.15 9.22 ± 0.21 16.30 ± 0.20 1.08 ± 0.13
  Ad-delE1B55 1.17 ± 0.05 1.70 ± 0.22 8.77 ± 0.22 36.84 ± 0.12 51.80 ± 0.28
  ZOL 0.86 ± 0.10 58.00 ± 0.54 25.64 ± 0.15 15.28 ± 0.27 0.82 ± 0.11
  ZOL + Ad-LacZ 0.70 ± 0.03 60.80 ± 0.20 25.40 ± 0.27 12.92 ± 0.28 0.77 ± 0.03
  ZOL + Ad-delE1B55 1.44 ± 0.22 19.93 ± 1.20 47.98 ± 1.01a 1.28 ± 0.32 0.64 ± 0.37
72 (−) 1.06 ± 0.02 76.33 ± 0.64 9.26 ± 0.23 12.68 ± 0.28 0.92 ± 0.21
  Ad-LacZ 0.51 ± 0.06 76.20 ± 0.37 8.68 ± 0.26 13.50 ± 0.46 1.41 ± 0.07
  Ad-delE1B55 6.67 ± 0.17 2.15 ± 0.23 5.12 ± 0.49 27.45 ± 0.26 59.21 ± 0.85
  ZOL 5.67 ± 0.23 59.46 ± 0.21 19.55 ± 0.57 14.86 ± 0.47 1.02 ± 0.07
  ZOL + Ad-LacZ 6.07 ± 0.13 61.94 ± 0.30 16.93 ± 0.16 14.56 ± 0.12 0.97 ± 0.11
  ZOL + Ad-delE1B55 8.56 ± 0.38a 7.77 ± 0.84 41.33 ± 1.20a 22.49 ± 0.42 20.77 ± 0.11
  1. Cells were treated with ZOL (80 μM) and/or either Ad-delE1B55 or Ad-LacZ (2 × 103 vp/cell) and cultured for 24–72 h. Cell cycle profiles were analyzed with flow cytometry. Averages with SEs are shown (n = 3)
  2. a p < 0.01; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ-, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells